Antonius M.J. VanDongen

This paper identifies Arc as a therapeutic target for Alzheimer's disease by showing small molecules targeting Tip60 and PHF8 inhibit Arc expression, suggesting a multi-target approach.

This paper reviews drug promiscuity, discussing its role in side effects and therapeutic potential, and proposes a computer modeling strategy to leverage it.

This study shows Arc regulates neuronal gene expression and is linked to Alzheimer’s disease pathophysiology.

This study generates AD patient-derived 3D brain organoids with PSEN2 mutation, showing increased Aβ42/Aβ40 ratio, asynchronous calcium transients, and neuronal hyperactivity.

The paper investigates how Arc-positive neurons, marked by long-term potentiation, show increased functional connectivity and network refinement compared to c-Fos-expressing neurons.

This study shows that Arc protein accumulates in astrocytes after neuronal activity, independent of astrocytic transcription, through intercellular transfer from neurons.